Ionis Pharmaceuticals

IONS

Market cap $13.2B

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA. “These data add to a growing body of evidence outlining the clinical.

Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 billion in peak annual product revenue, $2 billion in royalties, and $6 billion in milestones from its robust pipeline and partnerships. Management guides for cash-flow breakeven by 2028, with initial FY2026 guidance and a strong balance sheet supporting continued clinical advancement.

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. “Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acut.

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.66 per share a year ago.

Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “This year,.